

[54] **CONTROLLED RELEASE POTASSIUM CHLORIDE**

[75] Inventors: Charles Hsiao, Cooper City, Fla.; Chi T. Chou, Monsey, N.Y.

[73] Assignee: Key Pharmaceuticals, Inc., Kenilworth, N.J.

[21] Appl. No.: 830,981

[22] Filed: Feb. 19, 1986

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 702,714, Feb. 19, 1985, abandoned.

[51] Int. Cl.⁴ A61K 9/32; A61K 9/36

[52] U.S. Cl. 424/476; 424/480; 424/482; 424/495; 424/497; 424/498

[58] Field of Search 424/480, 473, 476, 482, 424/495, 497, 498

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,538,214	11/1970	Polli et al.	424/473
4,519,801	5/1985	Edgren	424/473
4,553,973	11/1985	Edgren	424/473
4,555,399	11/1985	Hsiao	424/480
4,629,620	12/1986	Lindahl et al.	424/473

4,666,703 5/1987 Kopf 424/473

Primary Examiner—Shep K. Rose

Attorney, Agent, or Firm—John J. Maitner; Stephen I. Miller; James Nelson

[57] **ABSTRACT**

A controlled release potassium chloride tablet is disclosed which is comprised of potassium chloride crystals having a mesh size of about 30 to about 50 mesh which are coated with a coating material comprised of ethylcellulose and hydroxypropylcellulose. The coated crystals form micro pellets which then can be compressed into tablets. The tablets disintegrate rapidly in an aqueous environment thus assuring a more uniform dissolution of the active component as compared with other types of controlled release potassium chloride dosage formulations. The distribution of the potassium chloride micro pellets over a wide surface area in the gastrointestinal mucosa aids in reducing the risk of gastrointestinal lesions. The formation of the coated micro pellets which disperse quickly upon contact with aqueous environment allow for the repeated chronic oral administration of a relatively large dose of potassium chloride (20 mEq).

12 Claims, No Drawings